FDA Approves Saphnelo Pen for Lupus Self-Injection
Key Questions
What is the Saphnelo Pen and for what condition was it approved?
The Saphnelo Pen is an autoinjector formulation of AstraZeneca's Saphnelo (anifrolumab), approved by the FDA for once-weekly subcutaneous self-injection in patients with systemic lupus erythematosus (SLE). It delivers a 120mg dose.
How does the Saphnelo Pen benefit lupus patients?
The pen enables self-injection at home, reducing the need for clinic visits and potentially improving treatment adherence based on prior trial data. This approval enhances access to SLE therapy amid growing lupus treatments.
What is the significance of the FDA approval for Saphnelo Pen?
The approval confirms rollout potential for this once-weekly autoinjector, as reported across multiple sources. It supports easier administration for SLE management.
AstraZeneca's Saphnelo (anifrolumab) autoinjector pen received FDA approval for once-weekly subQ use in SLE, reducing clinic visits and boosting adherence based on prior trial data. Multiple reports confirm rollout potential. Impacts treatment access amid growing lupus therapies.